Navigation Links
EntreMed's ENMD-2076 Active in Solid and Hematological Cancers
Date:11/16/2009

ROCKVILLE, Md., Nov. 16 /PRNewswire-FirstCall/ -- EntreMed, Inc. ( ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of data for the Phase 1 study for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, in leukemia patients. The Company also announced that it has selected ovarian cancer as an initial Phase 2 indication.

Phase 1 Leukemia Data

Initial data for the Phase 1 clinical study with ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML) were presented by principal investigator, Dr. Karen Yee, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held this week in Boston, Massachusetts. Early results for the study in hematological cancers demonstrated that ENMD-2076, administered orally as a single agent, was well tolerated. Data for 15 evaluable patients showed that one patient achieved a CRi (complete remission with incomplete hematological recovery) and two patients achieved a morphologic leukemia-free state (MLFS). Three additional patients experienced 11%, 14%, and 65% reductions in marrow blast count. The AML study continues to enroll patients and pharmacodynamic and pharmacokinetic activity is being monitored.

Ovarian Cancer - Initial Phase 2 Indication

While early Phase 1 data from the leukemia study are encouraging, the Company has selected ovarian cancer as its initial Phase 2 indication. This decision is supported by data from the ongoing Phase 1 study with ENMD-2076 in patients with solid tumors where of the 20 ovarian cancer patients, tumor and tumor marker responses were demonstrated in 45% of patients. In addition, another 15% have shown clinical benefit including reductions in tumor size, improvement in symptoms, or both. The decision is further supported by robust preclinical data and the need for additional active age
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
2. EntreMed Presents Initial Clinical Results for ENMD-2076
3. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
4. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
5. Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National Active Lifestyle Skincare Destinations
6. Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds
7. Accurays Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers
8. MolSofts New Technology Brings Online Publications to Life in Fully Interactive 3D
9. Medcos 2010 Medicare Prescription Drug Plan Helps People Take an Active Part in Lowering Prescription Costs
10. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
11. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... and FARMINGTON, Conn. , ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of Series E warrants to purchase 21,917,808 ... warrants to purchase 2,191,781 shares of its common ...
(Date:7/6/2015)... , July 6, 2015  Impax Laboratories, Inc. ... Hsu , Ph.D. has resigned from the Company,s Board ... Dr. Hsu was a co-founder of Impax in 1995 ... Officer from October 2006 until April 2014. ... Wilkinson , Impax,s President and Chief Executive Officer stated, ...
(Date:7/6/2015)... DIEGO , July 6, 2015  OncoSec Medical ... DNA-based intratumoral cancer immunotherapies, today announced the appointment of ... position of Vice President of Market Development, effective July ... responsible for evaluating, designing, and executing on the company,s ... "I,m very excited to welcome Joann to ...
Breaking Medicine Technology:Palatin Technologies Completes $30 Million Financing 2Palatin Technologies Completes $30 Million Financing 3Palatin Technologies Completes $30 Million Financing 4Palatin Technologies Completes $30 Million Financing 5Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 2Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 3Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 4Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 5OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3
... production, increasing blood ... flow, muscle oxygen supply, HOBOKEN, N.J., Oct. ... Hypertension Research reveals Pycnogenol(R),(pic-noj-en-all), an antioxidant plant extract from the bark ... oxide,(NO) production which leads to an increase in blood flow and ...
... Developed Through Joint Venture Between Bristol-Myers Squibb, ... Its Kind in HIV Treatment -, PRINCETON, ... Bristol-Myers Squibb Company (NYSE: BMY ) and ... that Health Canada has approved ATRIPLA(R),(efavirenz 600 mg/emtricitabine ...
Cached Medicine Technology:New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 2New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 2Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 4Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 5Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 6Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 7Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 8Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 9
(Date:7/5/2015)... ... ... Women's Excellence in Wellness, powered by Movestrong announces parent/child fitness classes ... families that want their children to stay active as well as spend time with ... place TUESDAYS at 4:30pm. Questions? Call 248-601-6683. Women’s Excellence in Wellness, powered by ...
(Date:7/4/2015)... ... 04, 2015 , ... Earlier in 2015, on Feb. 26, ... member survey , detailing the most common plastic surgery and minimally invasive cosmetic ... data down into charts detailing demographic trends and regional preferences. With a focus ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... on July 2nd creating a buzz of media attention. In an effort to ... by HonestyFirstReviews.com's Tiffany Hendricks. , "These days many people are feeling overwhelmed by ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. Smith, ... retained to lead a national president recruitment for Regional Care, Inc. ... industry, B. E. Smith has recently placed more than 1,000 healthcare executives into ...
(Date:7/3/2015)... ... July 03, 2015 , ... Jennifer Renee Hanes, DO is ... Room , the largest network of independent freestanding emergency rooms in the United States. ... of our Sienna Plantation facility,” said Executive Medical Director of First Choice Emergency Room, ...
Breaking Medicine News(10 mins):Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 2Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 3Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3
... from Japan specifically for event -, MCLEAN, ... robotic baby,harp seal more effective than real, live ... with dementia and other aging-related,illnesses?, Come find ... when Vinson Hall,Retirement Community (VHRC) in McLean, Va., ...
... Study Published in Journal of Occupational and Environmental Medicine, Investigates ... ... Resource Utilization, PHILADELPHIA, May 12 High ... total,healthcare costs, according to a new study published this month ...
... (SPECT), researchers in The Netherlands were able to ... with generalized social anxiety disorder (also known as ... cause for the dysfunction. , The study, which ... Journal of Nuclear Medicine, compared densities of elements ...
... diet to look more attractive. Fish diet to avoid ... and getting eaten as a result. , That is the ... researchers from the ARC Centre of Excellence for Coral Reef ... Current Biology. , The same team who recently revealed fish ...
... May 12 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer ... operating room, today announced financial results for the first,quarter ended ... dollar amounts are expressed in US dollars., Q1 ... 14 new SPY systems installed, 22% increase ...
... the following preliminary,unaudited net sales results for the month of April 2008 by segment:, , ... (Preliminary and Unaudited) ... MONTH OF APRIL ... ...
Cached Medicine News:Health News:Paro, the World's Only Robotic Baby Harp Seal - Designed Specifically for Therapy - to be Focus of Industry Event at Vinson Hall Retirement Community in McLean, Va., June 2 2Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 2Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 3Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 4Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 5Health News:Are anxiety disorders all in the mind? 2Health News:Fish diet to avoid fights 2Health News:Novadaq Reports Financial Results for the First Quarter of 2008 2Health News:Novadaq Reports Financial Results for the First Quarter of 2008 3Health News:Novadaq Reports Financial Results for the First Quarter of 2008 4Health News:Novadaq Reports Financial Results for the First Quarter of 2008 5Health News:Novadaq Reports Financial Results for the First Quarter of 2008 6Health News:Novadaq Reports Financial Results for the First Quarter of 2008 7Health News:Novadaq Reports Financial Results for the First Quarter of 2008 8Health News:Novadaq Reports Financial Results for the First Quarter of 2008 9Health News:Novadaq Reports Financial Results for the First Quarter of 2008 10Health News:Novadaq Reports Financial Results for the First Quarter of 2008 11Health News:NBTY Announces Preliminary Unaudited Net Sales Results for April 2008 2
... excellent classical blood film stain used ... marrow. Erythrocytes stain pink to buff ... pale pink. Leukocyte nuclear chromatin stains ... "ground glass" blue and lymphocyte cytoplasm ...
RABIT (Rapid Automated Bacterial Impedance Technique) has been developed by Don Whitley Scientific over several years with the aid of leading product and computer design consultants....
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
Albumin reagent is used for the quantitative determination of albumin concentration in human serum....
Medicine Products: